In fact, in ELITE (Evaluation of Losartan in the Elderly study), VALIANT (VALsartan In Acute myocardial iNfarcTion), VAL-HEFT (Valsartan Heart Failure Trial) and CHARM (Candesartan in Heart failure - Assessment of moRtality and Morbidity) [14,214–217], ARB were never superior to ACE inhibitors. Here, ACE is linked to heart failure.